Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9035361 | 0.81 | HPGD (0.57) | MEN1KMT2AHPGDRAB9ANPC1 | |
| SCHEMBL1660160 | 0.81 | FFAR1 (0.65) | MEN1KMT2AUSP2HPGDRAB9A | |
| SCHEMBL787870 | 0.81 | PKM (0.62) | MEN1KMT2AUSP2HPGDRAB9A | |
| SCHEMBL7224268 | 0.80 | MEN1 (0.44) | MEN1KMT2AHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL20577869 | 0.80 | HPGD (0.58) | HPGDRAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL11217368 | 0.79 | RAB9A (0.56) | MEN1KMT2AUSP2HPGDRAB9A | |
| SCHEMBL10959070 | 0.79 | RAB9A (0.45) | MEN1KMT2AUSP2HPGDRAB9A | |
| SCHEMBL11217371 | 0.79 | SMN1; SMN2 (0.66) | MEN1KMT2AUSP2HPGDRAB9A | |
| SCHEMBL4505089 | 0.79 | ALDH1A1 (0.50) | KMT2ARAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL5444019 | 0.79 | HPGD (0.38) | MEN1KMT2AUSP2HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795144-B2 | Inhibitors of RAC1 and uses thereof for treating cancers | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-10-24 | — | — | US | disclosed |
| US-11795144-B2 | Inhibitors of RAC1 and uses thereof for treating cancers | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-10-24 | — | — | US | disclosed |
| WO-2018224563-A9 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2021-04-22 | — | — | WO | disclosed |
| US-20200095199-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | NANTES UNIVERSITE (FR) | 2020-03-26 | — | — | US | disclosed |
| EP-3296302-B1 | CHIRAL SPIRO PHOSPHORUS-NITROGEN-SULPHUR TRIDENTATE LIGAND, AND PREPARATION METHOD AND APPLICATION THEREOF | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2020-02-12 | — | — | EP | disclosed |
| US-10550138-B2 | Chiral spiro phosphorus-nirogen-sulphur tridentate ligand, preparation method and application thereof | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2020-02-04 | — | — | US | disclosed |
| US-20180141966-A1 | CHIRAL SPIRO PHOSPHORUS-NIROGEN-SULPHUR TRIDENTATE LIGAND, PREPARATION METHOD AND APPLICATION THEREOF | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2018-05-24 | — | — | US | disclosed |
| US-20180141966-A1 | CHIRAL SPIRO PHOSPHORUS-NIROGEN-SULPHUR TRIDENTATE LIGAND, PREPARATION METHOD AND APPLICATION THEREOF | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2018-05-24 | — | — | US | disclosed |
| EP-3296302-A1 | CHIRAL SPIRO PHOSPHORUS-NITROGEN-SULPHUR TRIDENTATE LIGAND, AND PREPARATION METHOD AND APPLICATION THEREOF | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2018-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795144-B2 | Inhibitors of RAC1 and uses thereof for treating cancers | RAC1, KRAS, CYRIB | MEN1 585/4885KMT2A 3254/4885USP2 4673/4885 |
| US-20180141966-A1 | CHIRAL SPIRO PHOSPHORUS-NIROGEN-SULPHUR TRIDENTATE LIGAND, PREPARATION METHOD AND APPLICATION THEREOF | TST, SPR, ROR1 | MEN1 3737/4885KMT2A 3505/4885USP2 4793/4885 |
| US-20200095199-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | RAC1, KRAS, CYRIB | MEN1 585/4885KMT2A 3254/4885USP2 4673/4885 |
| US-10550138-B2 | Chiral spiro phosphorus-nirogen-sulphur tridentate ligand, preparation method and application thereof | TST, SPR, ROR1 | MEN1 3737/4885KMT2A 3505/4885USP2 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.